Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming ...

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...

As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

Patrizia Cavazzoni, the director of the FDA’s Center for Drug Evaluation and Research, said in a letter last week that the demand for Zepbound and Mounjaro is being met, negating the need for ...

That’s an all-time record, CDER Director Patrizia Cavazzoni said, as she released the drug center’s annual approval report for 2024.

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...

The US Food and Drugs Administration (FDA) has confirmed that its director of the Centre for Drug Evaluation and Research (CDER), Patrizia Cavazzoni, has announced her resignation ahead of Donald ...